SCHEMBL3405552

SCHEMBL3405552

CCOC(=O)CCn1c(=O)ccc2ccc(Br)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT2B Q92831 1/20 0.43
ALDH1A1 P00352 5/20 0.43
KDM4E B2RXH2 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
TNF P01375 3/20 0.40
LMNA P02545 1/20 0.39
CNR2 P34972 2/20 0.38
JAK2 O60674 1/20 0.38
PAK4 O96013 1/20 0.38
NTRK1 P04629 1/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
CSF1R P07333 1/20 0.38
RET P07949 1/20 0.38
MET P08581 1/20 0.38
PDGFRB P09619 1/20 0.38
PIM1 P11309 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3214955 0.85 KAT2B (0.43) KAT2BALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL3403616 0.84 MTNR1A (0.46) KAT2BALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3229548 0.83 ALDH1A1 (0.51) KAT2BALDH1A1KDM4ETNFCNR2
SCHEMBL3410183 0.81 KMO (0.56) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL3785882 0.78 KDM4E (0.51) ALDH1A1KDM4ESMN1; SMN2MEN1MAPK1
SCHEMBL25865290 0.78 KMO (0.52) ALDH1A1
SCHEMBL3782219 0.76 KDM4E (0.48) KAT2BALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL30355117 0.76 BTK (0.46) KAT2BALDH1A1KDM4ESMN1; SMN2KMT2A
SCHEMBL24515647 0.73 TNF (0.55) KAT2BALDH1A1MEN1KMT2ATNF
SCHEMBL20553630 0.73 TNF (0.52) ALDH1A1TNFLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2254887-B9 OXAZOLIDINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-05-29 EP disclosed
US-8349826-B2 Oxazolidinone derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2013-01-08 US disclosed
EP-2254887-B1 OXAZOLIDINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2012-12-19 EP disclosed
US-20100331308-A1 OXAZOLIDINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-12-30 US disclosed
EP-2254887-A1 OXAZOLIDINONE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-01 EP disclosed
WO-2009104159-A1 OXAZOLIDINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331308-A1 OXAZOLIDINONE DERIVATIVES OXA1L, UQCRB, O60361 KAT2B 1278/4885ALDH1A1 367/4885KDM4E 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.